Skip to main content
Công ty Cổ phần Dược phẩm Imexpharm logo

Công ty Cổ phần Dược phẩm Imexpharm — Investor Relations & Filings

Ticker · IMP ISIN · VN000000IMP0 HSX Manufacturing
Open in API
Filings indexed 381 across all filing types
Latest filing 2025-05-22 Regulatory Filings
Country VN Viet Nam
Listing HSX IMP

About Công ty Cổ phần Dược phẩm Imexpharm

www.imexpharm.com

Imexpharm Corporation is a prominent pharmaceutical company with over 48 years of experience in the manufacturing, compounding, and distribution of high-quality pharmaceutical products. The company operates extensive production facilities, including three EU-GMP certified factory clusters and one WHO-GMP certified cluster, making it a leader in EU-GMP compliant manufacturing. Imexpharm is recognized as a top producer of antibiotics and offers a diverse product portfolio encompassing injectable and oral antibiotics, cardiovascular, ophthalmic, musculoskeletal, respiratory, and digestive system treatments, alongside vitamins, minerals, and health protection foods. With 28 product registrations for 11 products in Europe, Imexpharm is dedicated to delivering effective and safe healthcare solutions to the community.

Recent filings

Filing Released Lang Actions
IMP: Giấy xác nhận thay đổi nội dung đăng ký doanh nghiệp
Regulatory Filings Classification · 90% confidence The document is a 24-hour regulatory disclosure submitted to the State Securities Commission and Ho Chi Minh Stock Exchange. It announces a change in the company’s registered business lines and includes a certification issued by the provincial finance department. There are no financial statements, earnings data, or meeting materials—this is a general compliance/regulatory announcement. It does not fit any specific report category, so it falls under the fallback “Regulatory Filings” category (RNS).
2025-05-22 Vietnamese
IMP: Điều lệ công ty sửa đổi ban hành tháng 04/2025 (đã điều chỉnh)
Governance Information Classification · 90% confidence The document is a 24-hour disclosure to the SSC and HOSE, but instead of merely announcing a report, it includes the full corporate charter (“Điều lệ”) of Imexpharm, detailing internal rules, governance structure, shareholder meetings, board of directors, audit committee, etc. This is a governance document describing the company’s internal governance practices. It is not a financial report, proxy statement, or simple publication notice, but the actual charter. Therefore it falls under Governance Information (CGR).
2025-05-15 Vietnamese
IMP: Điều chỉnh Biên bản họp và Nghị quyết ĐHĐCĐ thường niên năm 2025
AGM Information Classification · 84% confidence The document is an official corporate disclosure to the State Securities Commission and Ho Chi Minh Stock Exchange regarding corrections to the 2025 Annual General Meeting’s resolution and minutes. It includes the full text of the corrected Resolution No. 01/2025 and Minutes No. 01/2025 of the AGM, with items such as approval of financial statements, profit distribution, dividend, auditor selection, etc. These are not preliminary solicitations or voting-count announcements but are the AGM materials themselves (i.e., the formal resolutions and minutes of the meeting). Therefore it should be classified as “AGM Information” (AGM-R).
2025-05-15 Vietnamese
IMP: Nghị quyết HĐQT về việc triển khai Dự án Tổ hợp Nhà máy Dược phẩm Cát Khánh
Regulatory Filings Classification · 86% confidence The document is a mandatory 24-hour regulatory disclosure filed with the Vietnamese SSC and Ho Chi Minh Stock Exchange, containing the Board of Directors’ resolution approving a new factory complex project. It is not a change in management (so not MANG), nor is it a full financial report, earnings release, or specialized filing (e.g., IR, ER, DIV). It is a general regulatory announcement with the text of the Board resolution, making it a Regulatory Filing (RNS).
2025-05-15 Vietnamese
IMP: Giấy xác nhận thay đổi nội dung đăng lý doanh nghiệp
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure filed by Imexpharm on the State Securities Commission and Ho Chi Minh Stock Exchange portals. It announces a change in the company’s enterprise registration (adding a new business line) and attaches a confirmation letter from the Dong Thap Provincial Department of Finance. This is not a financial or management report but a compliance filing notifying regulators of corporate registration changes, making it a general regulatory announcement. Therefore, it falls under Regulatory Filings (RNS).
2025-05-12 Vietnamese
IMP: Quy chế nội bộ về quản trị công ty
Governance Information Classification · 85% confidence The document is a formal disclosure on the State Securities Commission and Hochiminh Stock Exchange portal announcing the attached full text of Imexpharm’s amended Internal Regulations on Corporate Governance, including detailed chapters on board procedures, shareholder meetings, audit committee operations, executive appointments, and other governance provisions. It is not an announcement of a report publication only, nor a financial report, but the actual governance policy document. This matches the definition for Governance Information (CGR).
2025-04-28 Vietnamese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.